Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors

HYMPAVZI’s safety profile was generally favorable

Bengaluru healthtech firm Biomoneta secures USFDA nod for air purifier

Captured microbes are then neutralized on engineered microbicidal surfaces

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development

Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Terray Therapeutics hits milestone in collaboration with Bristol Myers Squibb

Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities

DBT, BIRAC and CEPI renew cooperation agreement for vaccine development

DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)